Revvity (Revvity) Change In Receivables : $-6 Mil (TTM As of Mar. 2024)

View and export this data going back to 1983. Start your Free Trial

What is Revvity Change In Receivables?

Revvity's change in receivables for the quarter that ended in Mar. 2024 was $37 Mil. It means Revvity's Accounts Receivable declined by $37 Mil from Dec. 2023 to Mar. 2024 .

Revvity's change in receivables for the fiscal year that ended in Dec. 2023 was $-9 Mil. It means Revvity's Accounts Receivable increased by $9 Mil from Dec. 2022 to Dec. 2023 .

Revvity's Accounts Receivable for the quarter that ended in Mar. 2024 was $589 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Revvity's Days Sales Outstanding for the three months ended in Mar. 2024 was 82.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Revvity's liquidation value for the three months ended in Mar. 2024 was $-3,242 Mil.

Revvity Change In Receivables Historical Data

The historical data trend for Revvity's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Change In Receivables Chart

Revvity Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-100.63

-398.85

165.59

66.09

-9.00

Revvity Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															34.42	-44.64	-20.70	21.92	37.19

Revvity Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6 Mil.

Revvity (NYSE:RVTY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Revvity's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	588.974	/	649.92	*	91
=	82.69

2. In Ben Graham's calculation of liquidation value, Revvity's accounts receivable are only considered to be worth 75% of book value:

Revvity's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1695.408	-	5586.209	+	0.75 * 588.974	+	0.5 * 414.029
=	-3,242

Revvity Change In Receivables Related Terms

Thank you for viewing the detailed overview of Revvity's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity (Revvity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

PKN:Germany PKN:Germany

Address

940 Winter Street, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121